Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
about
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondAdverse Effects of GLP-1 Receptor AgonistsThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingLixisenatide as add-on therapy to basal insulinTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesUpdate on the treatment of type 2 diabetes mellitusTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsEfficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsThe efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trialsLixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusAdding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
P2860
Q26749089-8DCA512B-7A96-4E7D-B10E-0F4DD0DB3701Q26771823-5AAF0665-D9B5-45D5-B3D0-29C1FC695CB3Q26799389-AFAC7647-E824-4963-95F7-0455771E5542Q26801346-E309790D-168E-4EAC-8D26-119BDC7B61A1Q26852590-654288DD-56EC-4857-B7E6-E01F4D4EAE87Q26992979-FCAB0110-1DCB-4815-8EA0-E00518A518FDQ27007547-DAB8B59D-092E-4F07-BAB0-503CB3CB95ADQ27021870-007018A8-A0EC-4AE6-8278-00AC4F65D59AQ27025423-FC04ADB5-5AD0-46BD-A5CD-CF077465C84AQ28073342-33E2BA6E-FCE8-4E0A-9A1C-13F6127B45D9Q28077026-313FF01F-9856-4231-8C71-C0C9AF188876Q30240808-0250311C-6BCD-44FD-9F13-BBF0A13258FAQ34726309-DEFE8981-23DD-46BB-A1FF-DE9DE25DDF1CQ35192193-F3F5135B-7230-4ED1-9AFF-C2807B2E733BQ36073461-9B0ADE9A-0701-4E6A-B598-4BF17193FE93Q36124485-487D3F60-E877-4F4D-B723-188B20C4C882Q36803151-37D4D5B7-0DE5-458C-94B6-33DAD93D7846Q36972371-AE02D373-9B88-4593-B8EA-FB5B9C67A621Q37106537-C44DBC38-22DA-48ED-9923-4806B3465667Q37106572-43953719-EDF5-455E-9752-A60CFA1E9075Q37340223-339B950B-DBDF-403B-8C55-F4A0F0A39F44Q37446672-E7534C04-88CF-4495-AED9-B3B1BED93710Q37510200-6D73FDEB-6BD0-45B5-B901-1E0DAA416209Q37639302-9DCEFA0D-6A48-40D7-8CF4-3C486775419DQ37737470-9CDA56E4-5C71-4B32-9681-E84233D5429FQ38126893-05809DC7-C4F4-400F-9376-5916B7ED01FFQ38148574-4357D628-66AA-4B70-8670-F59738040D67Q38154623-B4F8A4B0-D021-4629-8485-B6BF12025F76Q38174283-2B502845-2A3B-4F5C-9B96-4CE5D7CD7592Q38183127-7EB4B08F-0354-431B-A5AB-DF81607FD71DQ38219488-4277ACEB-8A6A-43EA-82A9-B24A187216FCQ38239573-E29ADA03-7EF0-421E-B8B2-8CA3507CFA71Q38243035-D47BDB8D-8915-4F56-A55F-54AA666E4612Q38264360-61BEF6F5-77AE-4159-ACE6-E5AC648CA07DQ38270132-C9C29FCE-FFD0-47A9-8D86-529B4C3135FAQ38286444-0CBBB8B0-87DC-4A31-B2C8-12B9F75F7517Q38536672-F579ABBA-12DC-42EB-A1AE-F5507B907B6CQ38542098-ACDEDE95-F019-4851-8B4D-04C89B58F17AQ38597109-A8A97F95-B72B-4AA8-AC39-C070F8624EA2Q38616170-5FA7D5A7-0605-4025-B507-003C99A4B9ED
P2860
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacodynamic characteristic ...... ently controlled on metformin.
@en
Pharmacodynamic characteristic ...... ently controlled on metformin.
@nl
type
label
Pharmacodynamic characteristic ...... ently controlled on metformin.
@en
Pharmacodynamic characteristic ...... ently controlled on metformin.
@nl
prefLabel
Pharmacodynamic characteristic ...... ently controlled on metformin.
@en
Pharmacodynamic characteristic ...... ently controlled on metformin.
@nl
P2093
P2860
P921
P356
P1476
Pharmacodynamic characteristic ...... ently controlled on metformin.
@en
P2093
P2860
P304
P356
10.1111/DOM.12076
P577
2013-02-25T00:00:00Z